Keywords: Novavax, Influenza vaccine, BARDA contract, USA
BARDA continues Novavax' influenza vaccine programs following in-process review
Article | 27 January 2013
USA-based clinical-stage biopharmaceutical group Novavax (Nasdaq: NVAX) Novavax says that the US Department of Health and Human Services, Biomedical Advanced ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
